Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. The company is generating healthy operating cash flows (around Rs. 250 crore for the current year) and plans to fund CAPEX primarily from internal accruals. CAPEX guidance is around Rs. 150 crore to Rs. 200 crore annually, funded internally. Future land acquisition and new plant setup for expansion will be funded from internal cash generation. No discussion or indication of raising external debt or equity was mentioned during the Q&A or closing remarks.

Any current/future capex/capital investment/strategic investment?

Current CAPEX for FY24 was Rs. 246 crore, with an average annual CAPEX guidance of Rs. 150-200 crore funded entirely from internal accruals. Recent CAPEX incurred includes spending on land acquisition near existing Punjab location (~30 km from current site) for future expansion and new plant setups. Planned CAPEX at this new location is intended to support revenue growth beyond the current Rs. 3,000 crore revenue target by 2028 from existing products. Growth CAPEX will focus on infrastructure improvements like automation and environmental system installations, expected to positively impact top

Future growth expectations in sales/revenue/volumes?

Company targets a revenue of Rs. 3,000 crore by FY28 from existing products, implying a CAGR of around 12%-13% per annum. Revenue growth guidance for FY25 is 10% to 12% for the company overall, including pharma and chemical segments. Ibuprofen segment expected to grow 10%-12% in FY25. Non-ibuprofen API segment to grow 40%-45% in FY25. Specialty chemical segment expected to remain in single-digit growth in FY25, with hopes of recovery later in the year. Export contribution from non-ibuprofen segment currently around 17%-18%, expected to increase to 25%-40% in FY25. Volume growth in non-ibuprofe

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance for FY25 is expected at 10% to 12% for the company as a whole, including Pharma and Chemical segments. EBITDA margin target is set at around 14% to 15% for FY25, improved from 12% in FY24. PAT margin guidance is around 7% to 8% for FY25, up from approximately 6% in FY24. For the longer term (up to FY28), topline is projected to grow annually by 12% to 13%, aiming to reach Rs. 3,000 crore from existing products by 2028. EBITDA margin target for FY28 is around 14% to 15%. Specialty chemical segment expected to remain in single-digit growth in the near term but with a grad

IOL ChemicalsQ4 FY24Pharmaceuticals & Biotechnology

IOL Chemicals Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹183.13P/E: 30.4Market Cap: ₹5.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Company targets a revenue of Rs. 3,000 crore by FY28 from existing products, implying a CAGR of around 12%-13% per annum.
Revenue growth guidance for FY25 is 10% to 12% for the company overall, including pharma and chemical segments.
Ibuprofen segment expected to grow 10%-12% in FY25.
Non-ibuprofen API segment to grow 40%-45% in FY25.
Specialty chemical segment expected to remain in single-digit growth in FY25, with hopes of recovery later in the year.
Export contribution from non-ibuprofen segment currently around 17%-18%, expected to increase to 25%-40% in FY25.
Volume growth in non-ibuprofen segment increased 10%-15% last year.
Paracetamol capacity is at 95%, with plans to increase capacity to support volume growth.
EBITDA margin target is 14%-15% by FY28, with a PAT margin around 7%-8% in FY25.

Margin guidance

Category 1

Revenue growth guidance for FY25 is expected at 10% to 12% for the company as a whole, including Pharma and Chemical segments.
EBITDA margin target is set at around 14% to 15% for FY25, improved from 12% in FY24.
PAT margin guidance is around 7% to 8% for FY25, up from approximately 6% in FY24.
For the longer term (up to FY28), topline is projected to grow annually by 12% to 13%, aiming to reach Rs. 3,000 crore from existing products by 2028.
EBITDA margin target for FY28 is around 14% to 15%.
Specialty chemical segment expected to remain in single-digit growth in the near term but with a gradual recovery anticipated.
Export contribution in the non-ibuprofen segment is expected to increase from around 20% to approximately 30%-40% in FY25, supporting revenue growth.

See what IOL Chemicals management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
The company is generating healthy operating cash flows (around Rs. 250 crore for the current year) and plans to fund CAPEX primarily from internal accruals.
CAPEX guidance is around Rs. 150 crore to Rs. 200 crore annually, funded internally.
Future land acquisition and new plant setup for expansion will be funded from internal cash generation.
No discussion or indication of raising external debt or equity was mentioned during the Q&A or closing remarks.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders of IOL Chemicals and Pharmaceuticals Limited. However, some relevant points inferred include: - The company is experiencing good queries and business inquiries domestically and for exports in the non-ibuprofen segment, indicating a healthy order inflow. - Exports for Metformin have substantially increased (~60%) compared to last year, suggesting growing demand and likely order buildup. - The company has secured approvals (e.g., ANVISA for Brazil) that enable penetration into new regulated markets, expected to increase future orders. - The Specialty Chemical segment is expected to recover gradually by the end of the year, implying increasing orders in that segment as well. - Overall, while specific order book numbers are not disclosed, growth in exports and approvals hint at a positive order pipeline for FY25 and beyond.

See what IOL Chemicals management said on order book — free account, 30 seconds.

Capex plans

Yes

Current CAPEX for FY24 was Rs. 246 crore, with an average annual CAPEX guidance of Rs. 150-200 crore funded entirely from internal accruals.
Recent CAPEX incurred includes spending on land acquisition near existing Punjab location (~30 km from current site) for future expansion and new plant setups.
Planned CAPEX at this new location is intended to support revenue growth beyond the current Rs. 3,000 crore revenue target by 2028 from existing products.
Growth CAPEX will focus on infrastructure improvements like automation and environmental system installations, expected to positively impact topline and bottom line over the next 2-3 years.
The Rs. 3,000 crore revenue target by 2028 pertains only to existing facilities/products; new CAPEX investments will expand revenue beyond this target.
No specific timelines announced for new product launches like Sitagliptin, with no planned launch in the current financial year.

Track IOL Chemicals — get its next earnings analysis in your feed

How does IOL Chemicals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisIOL Chemicals

Rev 3Mar 1

See where IOL Chemicals sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does IOL Chemicals rank in Pharmaceuticals & Biotechnology?

Compare IOL Chemicals against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What IOL Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →